Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANGN Angion Biomedica		$6.48	$0.46 ▼ $2.04	$30.11M	0.6	86,718 shs	224,800 shs
HYPD Hyperion DeFi	$7.23 -7.7%	$8.81	$0.85 ▼ $75.18	$43.87M	2.42	857,540 shs	476,745 shs
LIAN LianBio	$0.05	$0.26	$0.27 ▼ $4.99	$5.43M	0.23	1.04 million shs	203 shs
PHXM PHAXIAM Therapeutics	$3.10	$3.10	$2.50 ▼ $13.00	$10.58M	2.35	2,472 shs	N/A

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANGN Angion Biomedica	0.00%	0.00%	0.00%	0.00%	0.00%
HYPD Hyperion DeFi	+4.96%	+24.48%	-40.82%	+580.81%	-88.62%
LIAN LianBio	0.00%	-7.52%	-88.23%	-74.27%	-84.58%
PHXM PHAXIAM Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANGN Angion Biomedica	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
HYPD Hyperion DeFi	0.3339 of 5 stars	1.0	0.0	0.0	0.0	2.3	0.8	0.6
LIAN LianBio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PHXM PHAXIAM Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANGN Angion Biomedica	0.00	N/A	N/A	N/A
HYPD Hyperion DeFi	2.00	Hold	$2.00	-72.34% Downside
LIAN LianBio	0.00	N/A	N/A	N/A
PHXM PHAXIAM Therapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANGN Angion Biomedica	$2.30M	0.00	N/A	N/A	$1.32 per share	0.00
HYPD Hyperion DeFi	$60K	674.80	N/A	N/A	($695.52) per share	-0.01
LIAN LianBio	N/A	N/A	N/A	N/A	$2.71 per share	N/A
PHXM PHAXIAM Therapeutics	N/A	N/A	N/A	N/A	$7.98 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANGN Angion Biomedica	-$38.81M	N/A	0.00	N/A	N/A	N/A	-47.53%	-40.55%	N/A
HYPD Hyperion DeFi	-$49.82M	-$58.40	N/A	N/A	N/A	-62,238.41%	N/A	-316.90%	N/A
LIAN LianBio	-$110.29M	-$0.81	N/A	N/A	N/A	N/A	-33.17%	-30.19%	N/A
PHXM PHAXIAM Therapeutics	-$240K	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest ANGN, HYPD, PHXM, and LIAN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/19/2025	Q1 2025	HYPD Hyperion DeFi	-$7.20	-$1.59	+$5.61	-$1.59	$1.60 million	$1.60 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANGN Angion Biomedica	N/A	N/A	N/A	N/A	N/A
HYPD Hyperion DeFi	N/A	N/A	N/A	N/A	N/A
LIAN LianBio	N/A	N/A	N/A	N/A	N/A
PHXM PHAXIAM Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANGN Angion Biomedica	N/A	20.00	20.00
HYPD Hyperion DeFi	N/A	0.34	0.34
LIAN LianBio	N/A	10.06	10.06
PHXM PHAXIAM Therapeutics	0.23	1.78	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANGN Angion Biomedica	17.00%
HYPD Hyperion DeFi	25.84%
LIAN LianBio	74.85%
PHXM PHAXIAM Therapeutics	0.40%

Insider Ownership

Company	Insider Ownership
ANGN Angion Biomedica	19.70%
HYPD Hyperion DeFi	10.86%
LIAN LianBio	7.59%
PHXM PHAXIAM Therapeutics	1.94%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANGN Angion Biomedica	3	30.11 million	24.18 million	Not Optionable
HYPD Hyperion DeFi	40	5.60 million	5.00 million	Optionable
LIAN LianBio	110	108.06 million	99.86 million	Not Optionable
PHXM PHAXIAM Therapeutics	49	3.41 million	3.35 million	No Data

ANGN, HYPD, PHXM, and LIAN Headlines

Recent News About These Companies

PHXM.FR | Phaxiam Therapeutics S.A. Annual Income Statement - WSJ

July 18, 2025 | wsj.com

Phaxiam Therapeutics SA (PHXM) Stock Forums - Investing.com

June 27, 2025 | investing.com

PHAXIAM Therapeutics Announces the Suspension of Trading in Its Shares Until Delisting

June 18, 2025 | finance.yahoo.com

PHAXIAM Therapeutics Announces Judicial Liquidation and Delisting

June 13, 2025 | finance.yahoo.com

PHAXIAM Therapeutics: New Postponement of the Offer Review Hearing

June 5, 2025 | finance.yahoo.com

PHAXIAM Therapeutics: Postponement of the Offer Review Hearing

May 23, 2025 | finance.yahoo.com

PHAXIAM Therapeutics: Extension of the Observation Period of the Receivership Procedure

May 5, 2025 | finance.yahoo.com

PHAXIAM Therapeutics: Update on the Receivership Procedure

April 25, 2025 | finance.yahoo.com

Phaxiam Therapeutics S.A.

March 28, 2025 | wsj.com

PHAXIAM THERAPEUTICS Announces the Launch of a Process to Find Buyers in the Context of its Receivership Procedure

March 15, 2025 | finance.yahoo.com

PHAXIAM Therapeutics Announces the Opening of a Receivership Procedure and the Postponement of its 2024 Financial Results Publication

March 6, 2025 | finance.yahoo.com

PHAXIAM Therapeutics: Press Release Regarding Suspension of Trading

March 6, 2025 | finance.yahoo.com

PHAXIAM Provides An Update On The Deployment Of Its Strategy To Maximize The Development Potential Of Phage Therapy

January 31, 2025 | businesswire.com

PHAXIAM Therapeutics Announces Its Financial Calendar for 2025

January 13, 2025 | finance.yahoo.com

PHAXIAM Therapeutics Announces Updated Real-Life Clinical Data From Patients Treated Under the Compassionate Status in Europe

January 7, 2025 | finance.yahoo.com

PHAXIAM Therapeutics Presents Clinical Data of the PhagoDAIR Pilot Study, With Results Confirming the Design of the GLORIA Phase II Clinical Study

December 30, 2024 | finance.yahoo.com

PHAXIAM Therapeutics presents an ambitious development strategy to take advantage of the rapidly evolving Phages therapy area

November 27, 2024 | globenewswire.com

PHAXIAM Presented its IVD Phagogram test and updated phage susceptibility tracking at the first "Phagogram Day"

November 18, 2024 | globenewswire.com

Phaxiam Therapeutics S.A.: PHAXIAM Reports Third-Quarter 2024 Financial Information

November 13, 2024 | finanznachrichten.de

PHAXIAM Reports Third-Quarter 2024 Financial Information

November 13, 2024 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANGN, HYPD, PHXM, and LIAN Company Descriptions

Angion Biomedica NASDAQ:ANGN

Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for chronic and progressive fibrotic diseases in the United States. The company develops ANG-3070, an oral tyrosine kinase receptor inhibitor for fibrotic diseases in kidney and lung. It also develops ROCK2 inhibitors for fibrotic diseases; CYP11B2, an inhibitor program for aldosterone-related diseases, including resistant hypertension, congestive heart failure, renal fibrosis, and hyperaldosteronism; and CYP26 for the degradation of retinoic acid. Angion Biomedica Corp. was incorporated in 1998 and is based in Uniondale, New York.

Hyperion DeFi NASDAQ:HYPD

$7.23 -0.60 (-7.66%)

As of 04:00 PM Eastern

Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.

LianBio NASDAQ:LIAN

$0.05 0.00 (0.00%)

As of 08/11/2025

LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03 for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.

PHAXIAM Therapeutics NASDAQ:PHXM

$3.10 0.00 (0.00%)

As of 08/8/2025

PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa. The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time